Services within kidney diseases

Accelerate your drug development by exploring clinical endpoints in our
rodent models of acute and chronic kidney diseases.

ReninAAV UNx db/db model of DKD

  • Hypertensive, type 2 diabetic mouse model of diabetic kidney disease
  • Adeno-associated virus-induced hypertension in uninephrectomized db/db mice
  • Progressive albuminuria
  • AI-assisted glomerulosclerosis scoring
See data
Publications
Posters

Get in touch

Please get in touch if you are interested in discussing how to get started with your study. Reach out to Principal Scientist Mette Viberg Østergaard mvo@gubra.dk Ph. +45 51226575

5/6 nephrectomy model of CKD

  • Subtotal nephrectomy rat model of chronic kidney disease
  • Surgical reduction of nephron mass for progressive kidney failure
  • Pronounced albuminuria and progressive loss of kidney function
  • Quantification and scoring of tubulointerstitial fibrosis and glomerulosclerosis
See data

UUO model of kidney fibrosis

  • Unilateral ureteral obstruction mouse model
  • Permanent surgical obstruction for induction of kidney fibrosis and inflammation
  • 7-day study period optimal for drug screening and dose-range-finding
See data

AI-assisted glomerulosclerosis
scoring using GHOST

At Gubra, we have developed the deep learning-based app GHOST (Gubra Histopathological Objective Scoring Technology) to automatically perform glomerulosclerosis scoring in rodent models of kidney disease.

Learn more

Look at the kidney in a new perspective

Quantification of kidney histomorphometric endpoints is time consuming and costly. At Gubra, we have automized our 3D imaging analyses after light sheet microscopy to quantify structural endpoints such as the number and volume of glomeruli in the intact mouse kidney.

Read publication: Whole-kidney 3D imaging in a mouse model of diabetic kidney disease (Front Cover. Kidney.360 – Vol. 1, Issue 6 – 25 Jun 2020)

Kidney webinar: How to improve the translatability of rodent models of diabetic kidney disease

Senior scientist Mette Viberg Østergaard introduces to the challenges of using current rodent models of diabetic kidney disease in drug discovery and development. Mette then presents an example of how translatability may be improved in a model of diabetic kidney disease in the setting of type 2 diabetes and hypertension.

Play webinar

Release time and duration: November 2020, 23 minutes

Main offerings

 

  • Kidney function assessment by transdermal GFR measurement
  • Biochemical assessment of plasma and urine markers of kidney function and injury
  • AI-assisted scoring of glomerulosclerosis
  • Histomorphometric quantification of tubulointerstitial fibrosis and inflammation
  • RNA sequencing and bioinformatics of bulk RNA as well as isolated glomeruli and tubulointerstitium
  • 3D kidney imaging and automated analyses of structural and functional kidney endpoints

Gubra Kidney in vivo study approach

We offer rodent models of advanced diabetic kidney disease and chronic kidney disease.

We apply sophisticated surgical techniques and induction of hypertension to accelerate kidney disease progression.

Clinical and preclinical endpoints are applied to improve model translatability.

 

Related Links:

Get in touch

Please get in touch if you are interested in discussing how to get your study started.

Mette Viberg Østergaard

Principal Scientist

mvo@gubra.dk
+45 51226575

© 2022 Gubra